(R) -Afatinib

• Description :

  (R) -Afatinib ((R) -BIBW 2992) is the Afatinib isomer. Afatinib (HY-10261) is an orally active, potent and irreversible dual specificity inhibitor of?ErbB?family (EGFR?and?HER2), with?IC50?values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for?EGFRwt, EGFRL858R, ?EGFRL858R/T790M?and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung?cancer? (NSCLC) and gastric?cancer[1].

• Product Name Alternative :

  (R) -BIBW 2992

• UNSPSC :

  12352005

• Target :

  C-Met/HGFR; EGFR; p38 MAPK

• Type :

  Reference compound

• Related Pathways :

  JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/r-afatinib.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CN(C)C/C=C/C(NC1=CC(C(NC2=CC(Cl)=C(C=C2)F)=NC=N3)=C3C=C1O[C@@H]4CCOC4)=O

• Molecular Formula :

  C24H25ClFN5O3

• Molecular Weight :

  485.94

• References & Citations :

  [1]Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7;27 (34) :4702-11.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [439081-17-1]